Trending...
- Green Energy Solar Expands with New Offices in Port St. Lucie, West Palm Beach, and Orlando
- xREnergy up as much as +3,094,634% on first day listed on the XRP Ledger. Ticker : $XRE
- The Tide Project Opens at Biennale Architettura 2025 in Venice Amplifying Youth Voices
COVINGTON, Ky., Oct. 10, 2023 ~ Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, has appointed Dr. Catherine Pearce, DHSc, MBA to its Board of Directors. The appointment is effective October 1, 2023.
Dr. Pearce is a biopharmaceutical executive with 25 years of experience in drug development, corporate development and C-Suite roles. She has led hundreds of global clinical trials at Medpace and built out business development and marketing teams there. At Teva Pharmaceuticals, she evaluated generics for repurposing which led to the approval of Uzedy for the treatment of schizophrenia. She also co-founded CinRx, a biotech incubator which developed 6 portfolio companies including CinCor which was acquired by AstraZeneca in February 2023. Additionally, she is the founder and CEO of JucaBio and a member of the Board of Trustees at Xavier University as well as an Advisor to several start-ups. Dr. Pearce holds a BS and MBA from Xavier University and a Doctorate of Health Sciences (DHSc) from Nova Southeastern University.
More on Ohio Pen
Scott Shively, CEO and President of Bexion Pharmaceuticals commented on the appointment: "We are excited to welcome Catherine as a key member of our Board as Bexion enters the next stage of our growth and progresses our clinical development program for BXQ-350." He added that her deep experience in shepherding drugs through clinical development and successfully closing transactions will be an asset to the company as it continues to progress.
Dr. Pearce expressed her enthusiasm about joining Bexion at this critical inflection point in their development: "I am excited to be joining Bexion at this critical inflection point in their development of BXQ-350. Helping to bring this promising medicine forward to patients as efficiently as possible is a great opportunity."
Cincinnati Children's Hospital & Medical Center which licensed its technology to Bexion stated that they are proud to have Dr. Pearce represent them on the Board: "Catherine is an accomplished biotech leader in both Cincinnati and the industry at large."
Dr. Pearce is a biopharmaceutical executive with 25 years of experience in drug development, corporate development and C-Suite roles. She has led hundreds of global clinical trials at Medpace and built out business development and marketing teams there. At Teva Pharmaceuticals, she evaluated generics for repurposing which led to the approval of Uzedy for the treatment of schizophrenia. She also co-founded CinRx, a biotech incubator which developed 6 portfolio companies including CinCor which was acquired by AstraZeneca in February 2023. Additionally, she is the founder and CEO of JucaBio and a member of the Board of Trustees at Xavier University as well as an Advisor to several start-ups. Dr. Pearce holds a BS and MBA from Xavier University and a Doctorate of Health Sciences (DHSc) from Nova Southeastern University.
More on Ohio Pen
- NBA Champion Lamar Odom Launches Anti-Addiction Meme Coin, Ushering in a Disruptive Innovation in Web3
- Aureli Construction Sets the Standard for Seamless Home Additions in Greater Boston
- Festo Features Multi-Axis Positioning Systems at Automate
- ScreenPoints Puts Film Investors in the Credits—and in the Money With New FinTech Platform
- Pathways to Adulthood Conference May 17 at Melville Marriott Honoring NYS Assembly Member Jodi Giglio, Suffolk County Legislator Nick Caracappa
Scott Shively, CEO and President of Bexion Pharmaceuticals commented on the appointment: "We are excited to welcome Catherine as a key member of our Board as Bexion enters the next stage of our growth and progresses our clinical development program for BXQ-350." He added that her deep experience in shepherding drugs through clinical development and successfully closing transactions will be an asset to the company as it continues to progress.
Dr. Pearce expressed her enthusiasm about joining Bexion at this critical inflection point in their development: "I am excited to be joining Bexion at this critical inflection point in their development of BXQ-350. Helping to bring this promising medicine forward to patients as efficiently as possible is a great opportunity."
Cincinnati Children's Hospital & Medical Center which licensed its technology to Bexion stated that they are proud to have Dr. Pearce represent them on the Board: "Catherine is an accomplished biotech leader in both Cincinnati and the industry at large."
Filed Under: Business
0 Comments
Latest on Ohio Pen
- L2 Aviation Celebrates Grand Opening of New Facility at Cincinnati/Northern Kentucky International Airport (CVG)
- Managing Summer Staffing Surges with Confidence: Why Name Badges Are a Must for Seasonal Success
- Visa Named Title Sponsor of Ascending Athletes' Business Owners Summits for NFL Entrepreneurs
- The Paris Court of International Arbitration Elects Dr. John J. Maalouf as its New President
- Whistleblower Seeks SEC and Shareholder Review of Cogent Communications' 2003 Acquisition of FNSI
- Sanders® Celebrates 150 Years with an Immersive NYC Experience, Food Truck Tour, and Exciting New White Chocolate Caramel Creations
- $56.7 Million Announced in Q1 2025 with Revenue Growth and Progress Toward NASDAQ Uplisting for AI Marketing Company: IQSTEL, Inc. Stock Symbol: IQSTD
- SAVVY MINING raised $500 million and launched BTC.XRP.DOGE cloud mining, increasing investors' returns by 30%
- New National Nonprofit Launches to Capture Firsthand Accounts of Adoption Stories
- The Tide Project Opens at Biennale Architettura 2025 in Venice Amplifying Youth Voices
- Wall Street analysts say BTC.XRP.DOGE cloud mining company SIX MINING is expected to achieve a 5-fold increase, allowing users to easily mine BTC
- Gen X Takes The Reins: New Book Guides Caregivers Juggling Parents, Kids, And Grandkids With Humor And Heart
- Fray Fitness Launches Memorial Day Sale and Veteran Organization Giveaway
- ABM for Good™ Launches First Project with Build Change
- ProfiSignal 20 Update Provides Significant Features
- ImagineX, in Collaboration with Qualys, Launches New mROC Services to Transform Enterprise Cyber Risk Management
- Ditch Micromanagement: New Leadership Book for Results-Driven, Accountability-Based Teams
- Jay Tapp was named Managing Director in British Columbia
- Hubei Heavy Equipment Makes a Striking Appearance at CIMT and Competes with International Brands
- 20 Patents Issued Worldwide, Cementing Company Leadership. First Ever Cable-Free 12-Lead ECG: HeartBeam, Inc. (Stock Symbol: BEAT)